Mazdutide1kits (10Vials)

Mazdutide (IBI362) – Details & Benefits 1. Basic Introduction Mazdutide (also known as IBI362 or LY3305677 ) is a first‑in‑class dual GLP‑1 / Glucagon receptor agonist developed by Innovent Biologics in collaboration with Eli Lilly. It is a long‑acting injectable peptide analog of oxyntomodulin (OXM) , designed for once‑weekly administration to support weight management, glycemic control, and overall metabolic health. Class : Dual GLP‑1R / GCGR agonist, metabolic peptide, anti‑obesity agent Route : Subcutaneous injection, once weekly Molecular weight : ~4563 Da Form : Sterile solution for injection (2 mg / 4 mg / 6 mg per 0.5 mL) Status : Approved in China (NMPA, 2025) for type 2 diabetes and chronic weight management; globally in Phase III development. 2. Mechanism of Action (Dual Target) Mazdutide works on two key metabolic receptors at the same time—this is what makes it stronger than single‑target GLP‑1 agonists. 1) GLP‑1 Receptor Activation (like Semaglutide) Slows gastric emptying → reduces appetite & food intake Increases glucose‑dependent insulin secretion → lowers blood sugar & HbA1c Suppresses glucagon overproduction → improves insulin sensitivity 2) Glucagon Receptor Activation (unique advantage) Increases energy expenditure → burns more calories at rest Stimulates hepatic fat breakdown → reduces liver fat & fights fatty liver Promotes “browning” of white fat → enhances fat oxidation Result : Less food intake + more fat burned = greater, sustainable weight loss + better metabolic profile . 3. Key Benefits & Effects (Proven in Clinical Trials) 1. Powerful & Rapid Weight Loss Average weight loss: ~12–15% in 48 weeks (6 mg once weekly) in obese adults Reduces waist circumference, visceral fat, and stubborn abdominal fat Superior to older GLP‑1s in head‑to‑head studies 2. Strong Glycemic Control (Type 2 Diabetes) HbA1c reduction: ~1.4–1.7% in 20–28 weeks Lowers fasting glucose & post‑meal spikes Improves beta‑cell function & insulin sensitivity 3. Liver Protection & Fatty Liver Improvement Reduces hepatic fat content significantly (MAFLD/NAFLD) Lowers liver enzymes (ALT/AST) → improves liver health Combines weight loss + liver repair in one treatment 4. Cardiovascular & Metabolic Benefits Lowers blood pressure (systolic −7~8 mmHg) Improves lipid profile: lower triglycerides, LDL, total cholesterol Reduces uric acid → supports kidney & joint health 5. Once‑Weekly Convenience & High Adherence One injection per week → better compliance than daily injectables Steady levels → fewer blood sugar fluctuations 4. Safety & Tolerability (Research / Clinical Profile) Generally well‑tolerated; most common effects are mild GI symptoms : nausea, diarrhea, decreased appetite (usually transient). Low hypoglycemia risk when used as directed. Not recommended for personal/family history of medullary thyroid carcinoma (MTC) or MEN2 syndrome (class‑wide warning for GLP‑1/GCGR agonists). 5. Summary Mazdutide (IBI362) is a next‑generation dual GLP‑1 / glucagon receptor agonist that delivers potent weight loss, robust glycemic control, and liver fat reduction in one once‑weekly injection. By combining appetite suppression (GLP‑1) with increased energy expenditure and hepatic fat breakdown (glucagon), it outperforms many single‑target GLP‑1s for body recomposition and metabolic health. Ideal for overweight/obesity, type 2 diabetes, and fatty liver (MAFLD) protocols.